Increased expression of the cell proliferation-associated polo-like kinase 1 (PLK1) and apoptosis-associated BCL-2 genes has been observed in different human malignancies. Inhibition of cell proliferation and reactivation of apoptosis are basic principles in anticancer therapy. The efficiency of this approach is often limited by insufficient targeting and delivery of anticancer drugs into the tumors. Phosphorothioate antisense oligodeoxynucleotides (ODNs) directed against PLK1 and BCL-2 were administered systemically via the tail vein into nude mice bearing A549, MDA-MB-435, and Detroit562 xenografts. To enhance tumor-specific uptake and to reduce systemic toxicity of antisense ODNs membrane electroporation transfer was applied in vivo. Northern and Western blot analyses were used to assess PLK1 and BCL-2 expression. Tumor mass was assessed after resection of tumors. All three cell lines and corresponding xenografts expressed high levels of PLK1 and were sensitive towards antisense PLK1 treatment. Antisense BCL-2 therapy was effective in tumors expressing high levels of BCL-2, but not in A549 cells and corresponding xenografts, which express low levels of BCL-2. Administration of antisense ODNs in a dose of 5 mg/kg, twice weekly during four weeks supported by the membrane electroporation transfer, eradicated 60-100% of the xenografted tumors. Antitumor effect in BCL-2 overexpressing MDA-MB-435 cells was synergistic for BCL-2 and PLK1 combination therapy. This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro-survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach.
Introduction
The development of cancer requires multiple independent genetic alterations. Alterations in critical genes lead to deregulated proliferation and suppression of apoptosis that contributes to immortalization and clonal evolution of certain precancerous progenitor cells. During carcinogenesis cells lose cell cycle checkpoint control leading to enhanced survival capacity of the clones with genetic errors, acceleration of proliferation, and increased genetic instability. DNA damage inhibits Cdkl and polo-like kinase 1 (PLK1) and arrests the cell cycle at multiple points in G2 and mitosis (Smits et al., 2000; van Vugt et al., 2001) .
The PLK 1, a mammalian cell cycle dependent, but cyclin-independent serine/threonine protein kinase (Lake and Jelinek, 1993; Golsteyn et al., 1994; Hamanaka et al., 1994; Holtrich et al., 1994; Donaldson et al., 2001) , is an important regulator of cell cycle progression including nuclear translocation of cyclin B1 (Toyoshima-Morimoto et al., 2001) , activation of the CDC25C-Cdkl amplification loop and the regulation of entry into mitosis. Furthermore, PLK1 activity is necessary for functional maturation of centrosomes in G2/early prophase and consequently, for the establishment of the bipolar spindle (Lane and Nigg, 1996) . PLK1 also regulates progression into mitosis by controlling the anaphase-promoting complex/cyclosome (APC/C) (Kotani et al., 1998) , the cell spindle checkpoint, and segregation of chromosomes. In addition, PLK1 is required for late mitotic events such as inactivation of Cdkl, activation of mitotic exit network, and cytokinesis (Lee et al., 2001) . When PLK1 function is impaired by a dominant-negative PLK1 mutant, by microinjected antibody against PLK1 or by antisense oligodeoxynucleotides (ODNs), cancer cells undergo aberrant mitosis and mitotic cell death (Lane and Nigg, 1996; Cogswell et al., 2000; Elez et al., 2000) . PLK1 is overexpressed in proliferating cells and in human carcinomas. Overexpression of PLK1 in primary human cancer is associated with enhanced mitotic activity and poor prognosis (Wolf et al., 1997; Knecht et al., 1999) .
BCL-2 forms a cation-specific channel in mitochondria, endoplasmatic reticulum, and nuclear lipid bilayers (Minn et al., 1997) , whereas Bax, the proapoptotic counterpart of BCL-2, forms an anion-selective channel (Antonsson et al., 1997) . Opening of the BCL-2 channels leads to loss of outer mitochondrial membrane integrity, disrupts electrostatic and osmotic gradients followed by release of calcium and intermembrane proteins such as cytochrome c and apoptosis-inducing factor (AIF) into the cytoplasm. Overexpression of BCL-2 interferes with activation of caspases by preventing the release of cytochrome c leading to resistance to programmed cell death and both inherent and acquired resistance to anticancer treatments (Reed, 1995; Grover and Wilson, 1996) . Antisense ODNs targeted at the open reading frame of BCL-2 mRNA (G3139) cause specific downregulation of BCL-2 expression, which leads to increased sensitivity to apoptosis, but is insufficient to induce cell death by itself (Webb et al., 1997; Jansen et al., 1998 Jansen et al., , 2000 .
Combination of antiproliferative (Monia et al., 1997; Wang et al., 1999) and antisurvival (Webb et al., 1997; Jansen et al., 1998) antisense therapy may effectively enhance apoptosis, reduce proliferation and thereby reduce tumor growth and progression. However, insufficient delivery of ODNs to their targets is a major problem in antisense therapy. Membrane electroporation has previously been used to facilitate uptake of DNA into tissues (Neumann et al., 1982 (Neumann et al., , 2000 DraghiaAkli et al., 1999) . In the present study, a combined antineoplastic strategy using antisense ODNs against mitosis associated PLK1 and antiapoptotic BCL-2 was applied. ODNs were administered systemically into NMRI nude mice bearing xenografts and enhanced tumor-specific uptake of antisense ODNs was achieved using in vivo membrane electroporation.
Results

Antisense phosphorothioate analogs downregulate PLK1 expression
To identify potent antisense ODNs against PLK1, we examined 56 antisense ODNs for their ability to reduce PLK1 expression in human cancer cells. Antisense sequences were designed against coding and noncoding regions of PLK1 mRNA. PLK1 expression was downregulated by treatment with the antisense JWG160-PLK1 and JWG370-PLK1. PLK1 protein expression was unchanged in cells subjected to no-treatment, DOTAP-lipofection, and corresponding mismatch ODNs (Figure 1a ). A549 human lung cancer cells were treated with increasing concentrations (0.5-2 mm) of JWG160-PLK1 antisense ODNs (Figure 1b and c) . Single administration of JWG160 (0.5 mm) reduced PLK1 mRNA to less than 20% of control (Figure 1b) . The median inhibitory concentration (IC 50 value) for JWG160-PLK1 to suppress PLK1 expression in A549 cells was approximately 0.35 mm. A similar response to JWG160-PLK1 was found in Detroit562 (human hypopharynx carcinoma cells) and in MDA-MB-435 (human breast carcinoma cells). Uptake of ODNs by cells was confirmed by fluorescence microscopy imaging using fluorescein-isothiocyanate (FITC) labeled ODNs targeted against the PLK1 mRNA transcript. Transfection efficiency in cultured A549 cells was 80-90%. All investigated cancer cell lines were found to express PLK1, whereas BCL-2 protein was strongly expressed only in MDA-MB-435 cells and primary stomach cancer (Figure 2a ). We next studied antiproliferative effects of JWG160 and G3139 in A549 and MDA-MB-435 cells (Figure 2b and c). Antiproliferative effects of JWG160 and pro-apoptotic effects of G3139 were evaluated based on the cell number and viability. The number of viable A549 and MDA-MB-435 cells was strongly reduced 2-4 days after treatment with antisense ODNs against PLK1 (Figure 2b and Figure 2a ). The viability of these cells was not influenced by G3139 and JWG160 (Figure 2d ). Similar results were obtained in human amniocites and mesangial cell, indicating that growth inhibitory effects of JWG160 and G3139 may be selective for cancer cells. In vivo electroporation for the efficient uptake of nonpermeant drugs into xenografted human tumors is based on the local application of electric pulses, which induce transient transport pores in the lipid parts of cell membranes. The locally restricted pores comprise o1% of the total cell membrane surface, but they enable sufficient uptake of systemically administered drugs into the cytosol and nucleus of targeted cells (Neumann et al., 1999) . Here, the efficiency of electroporative uptake of antisense phosphorothioate ODNs in vivo is shown for A549 and MDA-MB-435 xenografted tumors. FITC-labeled ODNs (5 mg/kg) were applied intravenously and membrane electroporation of the tumors applied locally. Tumors were resected 24 h later and the distribution of the FITC- (Figure 4a ), in spite of the lack of detectable BCL-2 expression in cultured A549 cells (Figure 2a) , and the corresponding lack of an effect of the BCL-2 antisense ODN on viability of A549 cells in culture. The moderate antitumor effect of the BCL-2 ODN on the size of A549 xenografts in vivo (Figure 4a ), and this seems likely to be because of an effect on angiogenesis. Indeed, the A549 tumors treated with G3139 showed a reduction of blood vessels (data not shown). G3139 had no additional effect in A549 xenografts when applied in combination with JWG160-PLK1 (Figure 4a ). No animal died during therapy courses and no sign of treatment-related toxicity 0 ) against BCL-2 without electroporation; G3139-electro, antisense ODN against BCL-2 with electroporation; G3139-MM mismatch control (5 0 -TCTCTCAGCATGTGCTAT-3 0 ); JWG160, antisense ODN (5 0 -CCCAAAAAGCGGCCCC-3 0 ) against PLK1 without electroporation, JWG160-electro, antisense ODN against PLK1 with electroporation, JWG160-MM; mismatch control with electroporation; G3139 and JWG160: combined BCL-2 and PLK1 antisense therapy with electroporation such as inflammation, bleeding, hepatomegaly, splenomegaly, or weight loss was observed in the animals during treatment.
Synergistic antitumor effects of JWG160-PLK1 and G3139-BCL-2 antisense ODNs in vivo
To determine whether pretreatment with G3139-BCL-2 antisense ODNs enhances the cytotoxic effect of JWG160-PLK1 antisense ODNs, we treated mice bearing MDA-MB-435 xenografts once weekly with G3139-BCL-2 antisense (5 mg/kg) and JWG160-PLK1 (5 mg/kg) for four consecutive weeks. Treatment with JWG160-PLK1 was always three days after application of G3139-BCL-2 (i.e., each ODN was applied only once weekly). Despite the lower dose for the respective oligo during combination therapy, synergistic effects of JWG160 and G3139 at the level of tumor size in MDA-MB-435 are observed. MDA-MB-435 express both PLK1 and BCL-2. In Detroit562 tumors, which express high levels of PLK1 and a modest level of BCL-2 (Figure 2a) , very high therapeutic responses were observed with either JWG160 or G3139 and with a combination of both ODNs (Figure 4b ). Combination therapy with JWG160-PLK1 and G3139-BCL-2 antisense ODNs eradicated 80% of Detroit562 xenografts. We observed strong synergistic antineoplastic effects of both antisense ODNs in BCL-2 expressing MDA-MB-435 xenografts (MDA-MB435: G3139-BCL-2: 0.05 g, CI, 0.02-0.07 g, Po0.0001, JWG160-PLK1: 0.05 g, CI, 0.04-0.06 g, Po0.0001, JWG160-PLK1 and G3139-0.07 g, Po0.0001, JWG160-PLK1: 0.05 g, CI, 0.04-0.06 g, Po0.0001, JWG160-PLK1 and G3139-BCL-2: 0.005 g, CI, 0.003-0.007 g, Po0.0001). All MDA-MB-435 tumors were completely eradicated after 4 weeks of sequential therapy with antisense ODNs against BCL-2 and PLK1 (Figure 4c ). In primary stomach cancer xenograft both JWG160-PLK1 and G3139-BCL-2 caused complete remission of eight of 15 (55%) tumors within 4 weeks of treatment (Figure 4d) . The growth inhibitory effect of tumors treated with antisense ODNs without electroporation was only 15-20% compared with tumors treated with antisense ODNs and electroporation (data not shown).
Downregulation of PLK1 and BCL-2 expression correlated with regression of tumors in nude mice
After tumor resection following 4 weeks of therapy and determination of tumor weight (Figure 5a ), PLK1 and 
Discussion
Recently, the molecular profiling approach has gained increased significance in the diagnosis and prognosis of multimolecular disorders such as cancer (Liotta and Petricoin, 2000) . , 1998) . In the present study, expression of PLK1 and BCL-2 was suppressed by antisense ODNs using liposome-encapsulated ODNs in cell culture experiments and membrane electroporation as a transfer method for enhanced uptake of the antisense inhibitors in mice. The data show that treatment of cancer cell lines (A549, Detroit562, and MDA-MB-435) and corresponding xenografts with antisense ODNs against mitosis-associated PLK1 and pro-survival-associated BCL-2 downregulates expression of their respective targets. This downregulation led to antitumor effects such as loss of cell viability, induction of apoptosis and arrest of tumor growth. The systemic application of nonencapsulated JWG160-PLK1 and G3139-BCL-2 combined with membrane electroporation resulted in a high cellular internalization of antisense ODNs in vivo.
The antisense effects of G3139-BCL-2 appeared selective for BCL-2 overexpressing cells and tumors. However, treatment of A549 tumors with G3139 showed moderate antitumor effect although we did not detect BCL-2 expression in A549 cells. The moderate antitumor effect of G3139 in A549 tumors could be due to antiangiogenic effects of G3139. Indeed, treatment with G3139 led to a significant reduction of blood vessels in treated tumors. In combination with antisense PLK1 therapy, we demonstrated synergistic antitumor effects in G3139-BCL-2 sensitive tumors (MDA-MB-435). The sequence specificity of phosphorothioate antisense ODNs was evident, although additional therapeutically beneficial sequence-dependent or sequence-independent nonantisense interactions cannot be excluded (Crooke and Lebleu, 1993; Stein, 1995; Khaled et al., 1996) .
Notably, mismatch controls corresponding to G3139 showed moderate downregulation of BCL-2 protein in certain tumors, indicating that the mismatch controls may have residual antisense or nonantisense capacity. However, we cannot exclude that downmodulation of PLK1 expression affects expression of BCL-2 through nonantisense mechanism. Known side effects of phosphorothioate ODN administration are hypotension, thrombocytopenia and increased clotting times (Henry et al., 1997; Sheehan and Lan, 1998) . None of these effects have yet been problematic in animal trials and ODN treatment also caused no apparent side effects in the present study. Polo-like kinases play multiple roles in different phases of mitosis. Overexpression of PLK1 can override checkpoint control (Smits et al., 2000) essential in proliferation and tumor formation (Smith et al., 1997) and correlates with poor prognosis in human tumors (Wolf et al., 1997; Knecht et al., 1999) . Expression of a dominant-negative PLK1 mutant induces mitotic arrest and mitotic catastrophe (Chan et al., 1999; Cogswell et al., 2000) . PLK1 loss-of-function mutants can suppress checkpoint defects (Sanchez et al., 1999) . The inhibition of PLK1 function in tumor cells could lead to cell cycle arrest at multiple points in mitosis and consequently to mitotic cell death.
Viability and survival of primary nontransformed cells such as amniocytes, mesangial cells, and skin fibroblasts were not affected by treatment with JWG160-PLK1 and G3139-BCL-2. The selectivity of antisense ODNs for cancer cells could be due to the lower expression of PLK1 and BCL-2 in nontransformed cells than in their transformed counterparts (Knecht et al., 1999, Figure 2a) . Furthermore, the rate of transfection of normal cells is lower (40%) than that of tumor cells (80-90%). In addition, PLK1 may have a different function in tumor cells than in normal cells (Lane and Nigg, 1996) . In normal cells, checkpoints and the program of apoptosis are fully functional. Owing to the lack of checkpoint control cancer cells are not able to arrest at G2/M and spindle checkpoints or to activate mitotic exit network, and will eventually die by aberrant mitotic processes.
Application of electric field pulses to tumors in vivo has been introduced as a novel drug delivery method, termed electrochemotherapy (ECT) (Mir et al., 1991; Mir and Reintgen, 1996; Heller et al., 1996 Heller et al., , 1998 . The electroporation method is currently evaluated for the in vivo treatment of various cancers using DNA, proteins and anticancer drugs such as bleomycin or cisplatin. Antisense compounds such as G3139-BCL-2 (Mr ¼ 6000) and JWG160-PLK1 (Mr ¼ 4200) phosphorothioate ODNs used here are relatively large molecules and do not cross the plasma membrane readily. In the present study, we have shown that electroporation of the tumors considerably enhanced tumor-specific uptake of antisense phosphorothioate ODNs against BCL-2 and PLK1 genes. Application of short high-voltage pulses induces transiently large electric potential differences creating transient transport pores in the proteolipid structure. This leads to enhanced uptake of antisense ODNs into the tumor cells.
A known side effect of in vivo cell electroporation is hyperthermia. Hyperthermia can induce heat injury in vivo leading to spontaneous premature condensation of chromosomes followed by nuclear fragmentation, multiple micronuclei and abnormal metaphase/anaphase and may eventually lead to cell death (Swanson et al., 1995) . Transient exposure of tissues to stress such as hyperthermia and rapid stress-induced synthesis of heat-shock proteins cause cell and tissue death. In the present study, we observed no significant inhibition of tumor growth in electroporated controls.
The data of the present study show that the efficiency of antiproliferative action of antisense ODN against PLK1 may be further strengthened by BCL-2 antisense ODN reducing the survival capacity of tumor cells. Clearly, the combination of selective silencing of target genes directed against proliferation and survival targets and sensitization of tumors with the biophysical method of site-selective, electroporative drug uptake represents a promising therapeutic antitumor strategy. Several tumor types such as melanoma, breast cancer or head and neck squamous cell cancer are potential models for the first clinical trials. In addition, it is necessary to develop several types of electrodes depending on tumor location, suitable for treatment of less accessible tumors.
Material and methods
Antisense ODNs
The antisense ODNs used in this study were 16-, 17-, 18-, and 20-mer with fully modified phosphorothioate backbones synthesized on an automated synthesizer (Perseptive 8909; BioSpring GmbH; Frankfurt, Germany). For deprotection ODNs were treated with concentrated ammonia for 16 h at room temperature. ODNs were purified by reverse phase chromatography. The lyophilisate was precipitated twice with 1 m NaCl/ethanol and then lyophilized again. The antisense ODN directed against human BCL-2 (G3139) was complementary to the translation initiation site (Webb et al., 1997; Jansen et al., 1998) . The following sequences-directed against PLK1 were identified as highly potent in cell culture experiments: JWG100:
The remaining ODN sequences will be made available from the authors upon request.
Treatment of human cancer cells with ODN
The human carcinoma cell lines A549, MDA-MB-435, and Detroit562 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), and used in cell culture and as nude mouse xenografts. In all, 2.5 Â 10 5 cells suspended in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS), antibiotics, and 2 mm l-glutamine were seeded in T25 cell culture flasks and grown at 371C in a 5% CO 2 -95% in a humidified incubator. After 24 h, cells (50-60% confluent) were treated with the appropriate ODN dissolved in sterile and de-ionized water for cell culture in the presence of the monocationic lipid l,2-dioleoyloxy-3-(trimethylammonio) propane (DOTAP, Roche Diagnostics, Mannheim, Germany) in 20 mm Hepes buffer (pH 7.4 with NaOH) and OptiMEM medium (Life Technologies, Rockville, MD, USA). After 4 h of incubation at 371C, the ODN-containing medium was replaced with normal cell culture medium containing 10% FCS, and the cells were incubated for additional 24 or 48 h. Cell viability was determined by trypan blue staining and cell number was determined by counting of trypan blue negative cells after the indicated times following transfection. Transfected and nontransfected cells showed 95-100% viability 24 h after transfection.
In vivo tumor model
Animal studies were performed with groups of 5-6 athymic nude mice (NMRI nu/nu, Harlan Winkelmann, Borchen, Germany), 8-10 weeks old. A549, Detroit562, and MDA-MB-435 cells (5 Â 10 6 ) were injected subcutaneously and serially passed by at least three consecutive transplantations before the start of electroporation-facilitated antisense therapy. Tumor fragments of about 25 mg were implanted subcutaneously into the left flank of the animals under urethane anesthesia. Treatment was initiated when the tumors had reached an average volume of 60-90 mm 3 . ODNs dissolved in saline solution were administered intravenously twice weekly as a bolus (200 ml) into the tail vein at a dose of 5 mg/kg. The animals were monitored by general clinical observation, determination of body weight, and tumor growth. After 4 weeks treatment the animals were killed, tumors excised and tumor mass assessed using a fine scale. For determining PLK1 or BCL-2 mRNA and protein in tumor xenografts, total RNA and protein were prepared from excised tumors and analyzed by Northern and Western blotting, respectively, as described below.
In vivo electric pulse application JWG160-PLK1 and G3139-BCL-2 ODNs, suspended in saline solution, were administered intravenously twice a week as a bolus into the tail vein. Each experimental condition included at least five animals per group. Each experiment was done in triplicate. Following application of ODNs electric pulses were applied percutaneously by positioning the tumor between two parallel stainless-steel electrodes placed on opposite sides of the tumor using conductive contact paste. The tumor was electroporated by applying five consecutive rectangular pulses of 400 V/cm field strength and 10 ms duration; the interval between the pulses was 1 s.
Fluorescence microscopy
Studies on intravenously injected unmodified (phosphodiester) ODNs have shown that the plasma half-life is approximately 5 min. The phosphorothioate modification leads to a significant prolongation in plasma half-life to 30-60 min. Phosphorothioate ODNs bind to serum albumin and alpha 2 macroglobulin and demonstrate biphasic pharmacokinetics (Agrawal et al., 1991) . Animal studies on ODN biodistribution have shown that ODNs administered intravenously, subcutaneously, or intraperitoneally accumulate primarily in the liver, kidney, and other organs of the reticuloendothelial system (Agrawal et al., 1991) . We applied fluorescein isothiocyanate (FITC)-labeled phosphorothioates ODNs i.v. into nude mice. After 5 min, tumors were electropermeabilized as described. After 24 h tumors were resected and frozen at À701C. Sections of 5 mm were subjected to fluoroscence microscopy imaging.
Northern blot analysis
Total RNA was isolated from homogenized tumors or from transfected cells using the RNeasy Mini Kit (Qiagen AG, Hilden, Germany). In all, 20 mg of total RNA was separated by electrophoresis in a denaturing 1% agarose/formaldehyde gel, transferred to nylon membranes and probed with a radioactive PCR-generated fragment of PLK1. Primers were generated on an Applied Biosystems 380A DNA synthesizer. Radiolabeling of the probe for Northern blotting was carried out by a standard PCR procedure using 150 mCi of a-32 P dCTP (6000 Ci/mmol). Radiolabeling of the antisense strands was performed using the following primers: PLK1-antisense: 5 0 -TGATGTTGGCACCCTTTCAGC-3 0 , GAPDH: sense: 5 0 -CACCCATGGCAAATTCCATG-3 0 , antisense: 5 0 -CATGG-TTCACACCCATGACG-3 0 . Hybridization was carried out in QuickHyb solution (Stratagene, La Jolla, CA, USA) for 1 h at 681C. Membranes were washed twice under high stringency conditions in 0.1 Â SSC, 1% SDS at 651C for 20 min and subjected to autoradiography overnight (Sambrook et al., 1989) . Subsequently, the membranes were stripped and rehybridized with another radioactive probe to have control over the quality and uniformity of mRNA loading under identical conditions. RNA was normalized using GAPDH mRNA levels.
Western blot analysis
Lysates from cells treated with ODNs and homogenates from resected tumors after 4-week therapy were subjected to Western blot analysis. Cellular proteins were extracted using 250 ml of extraction buffer (RIPA) per T25 cell culture flask. A total of 20 mg of protein was separated by electrophoresis in SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Blots were incubated with anti-Plk-1 or anti-BCL-2 antibody (Transduction Laboratories, Lexington, KY, USA). Immune complexes were visualized using appropriate horseradish peroxidase-conjugated secondary IgG and the chemiluminescence system (Amersham-PharmaCIa, Uppsala, Sweden). For reprobing, blots were incubated in stripping buffer (62.5 mm Tris-HCl, pH 6.7, 2% SDS, and 100 mm 2-mercaptoethanol) at 501C for 30 min, washed extensively with PBS, blocked and reprobed with anti-b-actin (Sigma, St Louis, MO, USA).
Measurement of cell proliferation
Antiproliferative effects were evaluated by cell number and viability as assessed by direct cell counting using the trypanblue (0.1%) exclusion method. The number of viable cells was measured daily for 4 days following treatment with JWG160-PLK1, JWG370-PLK1 and G3139-BCL-2 antisense ODNs, or scrambled control ODNs. The mean of three counts was taken at each time point and the percentage of viable cells given.
Immunohistochemistry and apoptosis assay
Mouse tissues and tumors grown in NMRI nude mice were histologically evaluated by hematoxylin and eosin staining. Proliferating cells were visualized by staining with Ki67 antibody (DAKO, Hamburg, Germany), and blood vessels with vWF antibody. Frozen sections (5 mm) were fixed in acetone (À201C, 2 min). Tissue sections were washed in Tris-buffered saline (TBS) and incubated with polyclonal rabbit anti-mouse Ki67 antibodies (dil. 1:25) and rabbit anti-mouse vWF (1:100) for 60 s at 371C in humified atmosphere. Slides were washed 3 times with TBS and incubated with horseradish labeled polymers conjugated antirabbit antibodies. The detection of programmed cell suicide in frozen tumor sections was performed by the TdT-mediated dUTP nick-end labeling assay for apoptosis (TUNEL, Roche Diagnostics, Mannheim, Germany).
Statistical analysis
The cell culture data represent mean and means7s.d. of at least three independent experiments. The in vivo data represent means and 95% CI of 10-15 independent determinations. Two-sided t-tests were used to determine statistically significant differences of tumor masses between the different groups. P values less than 0.05 were considered to be statistically significant.
